Hani Abouhalka

Hani Abouhalka is the Company Group Chairman for Johnson & Johnson (J&J) Medical Devices Companies. He is responsible for the company's Medical Device businesses in Europe, Middle East & Africa (EMEA), which includes surgical technology, orthopaedics, cardiovascular and specialty solutions directed at delivering clinical and economic value to healthcare systems.

A purpose-driven and global leader, Hani brings with him an outstanding 20-year record of driving transformational growth across EMEA's developed and emerging markets, building high-performing teams and championing Johnson & Johnson values.

Throughout his career, Hani has held several leadership roles of increasing responsibility across multiple disciplines (business and strategy development, health economics, operations, and management roles), businesses (Medical Devices, Ethicon, Biosurgery, and Cordis) and geographies, from the US to Lebanon and the UAE to the Benelux region and the UK. Before being appointed to his current role in December 2018, Hani served as Vice President, Medical Devices Strategy Development & Global Operations, focused on advancing the process and execution of the global business strategy, improving portfolio value and implementing critical capabilities.

Known for putting the needs of patients first, Hani is passionate about strengthening Johnson & Johnson's footprint in key markets and advancing diverse talent across the enterprise. He is also committed to shaping sustainable solutions that positively impact the health of millions of people.

Hani is the executive sponsor of the Women's Leadership & Inclusion employee resource group in EMEA, which supports the advancement of gender equality at J&J. He also serves as Board Member of the Johnson & Johnson Foundation, a registered charity responsible for managing J&J's Global Community Impact programs and activities across EMEA.

Hani holds a Bachelor's degree in Biology from Arizona State University and a Master's degree in International Business from Thunderbird, The Garvin School of International Management.

COVID-19 and its impact has been unprecedented. Nowhere is this more visible than in our healthcare sector, where hospital and ICU capacity have been stretched to their limits. Healthcare professionals and other frontline staff have performed heroic yet exhausting feats – delivering superhuman efforts to ensure continuity of care. I’m proud that the MedTech industry has supported them, rethinking the delivery of care through the swift uptake of digital solutions. For example, virtual surgeon and healthcare professional (HCP) training was developed rapidly, while patient interaction tools for virtual assessment and planning were developed and leveraged online. This brought real benefits for HCPs and patients, with advanced data analytics in surgery helping to improve outcomes. We saw almost twice as many users utilise virtual or telehealth services in one year (increasing from 15% to 28%), as well as new, virtual HCP commercial interactions, due to COVID-19 restrictions. As healthcare embraced digital tools, relevant online content was available for customers. It is vital that the benefits of going digital are sustained into the future. As an industry we must continue to use digital solutions in the post-COVID world, fundamentally changing the way we deliver care. If we succeed in doing this together, we can support better patient outcomes, increase healthcare system capacity and reduce the cost of care delivery. The industry already offers an impressive array of digital tech to help with the immediate challenges of COVID-19 and its aftermath – particularly for clearing the backlog of elective procedures. Operating Rooms (ORs) can connect to the cloud to collect and analyse surgical video for surgeon learning; patient-specific 3D anatomical reconstructions can help surgeons navigate procedures just by using that patient’s CT or MRI scan; digital workflows can enhance teamwork and drive consistency in the OR. Digital surgery represents the potential for a...